Quantcast
Last updated on April 23, 2014 at 11:05 EDT

Latest DioGenix Inc. Stories

2014-01-27 08:27:45

GAITHERSBURG, Md., Jan. 27, 2014 /PRNewswire/ -- DioGenix, Inc. announced today new data supporting the clinical validation of MSPrecise®, its proprietary next-generation sequencing (NGS) assay for the identification of patients with multiple sclerosis (MS) at first clinical presentation. The prospective study met its primary endpoint by demonstrating the ability of MSPrecise to diagnose patients with MS. The test performed consistently with previous clinical studies, having a...

2013-12-05 08:29:14

GAITHERSBURG, Md., Dec. 5, 2013 /PRNewswire/ -- DioGenix, Inc. announced today that it raised $3.2 million in a private financing consisting of new individual investors and returning investors including life sciences fund Nerveda, LLC. The financing follows recent interim results from a prospective clinical trial of DioGenix' MSPrecise®, a next-generation sequencing assay, which continues to show that it can accurately identify patients with multiple sclerosis (MS) at first...

2013-03-18 08:29:03

GAITHERSBURG, Md., March 18, 2013 /PRNewswire/ -- DioGenix, Inc. announced today that the United States Patent and Trademark Office has issued a patent that broadly protects DioGenix' proprietary next-generation sequencing assay, MSPrecise(TM), that has shown in recent clinical studies to accurately identify patients with multiple sclerosis (MS) at first clinical presentation. "This patent, combined with DioGenix' expertise in developing novel molecular tests, is a strategic necessity, as...

2012-12-18 08:27:46

GAITHERSBURG, Md., Dec. 18, 2012 /PRNewswire/ -- Molecular diagnostics company DioGenix, Inc. today announced it raised $1.5 million in Series B financing. Existing investors including life sciences fund Nerveda LLC participated in the round to support a prospective, multi-site clinical trial to validate MSPrecise(TM), DioGenix' proprietary next-generation sequencing test for the early identification and diagnosis of multiple sclerosis (MS). In a recently completed study, MSPrecise...

2012-11-08 08:34:52

GAITHERSBURG, Md., Nov. 8, 2012 /PRNewswire/ -- DioGenix, Inc., a company developing molecular diagnostics for the early diagnosis and monitoring of immune-mediated neurological diseases, today announced its lead product MSPrecise(TM) outperformed the specificity of the current standard of care for cerebral spinal fluid (CSF) analysis in patients suspected of having multiple sclerosis (MS) by almost two to one with no loss of sensitivity. MSPrecise is a proprietary...

2012-11-08 08:34:49

GAITHERSBURG, Md., Nov. 8, 2012 /PRNewswire/ -- DioGenix, Inc. today announced an alliance with Fast Forward, a subsidiary of the National Multiple Sclerosis Society, to develop a novel blood test for multiple sclerosis (MS). Fast Forward will provide up to $500,000 as part of a Sponsored Research Agreement that will enable DioGenix to expand an ongoing clinical trial of its MS diagnostic, MSPrecise(TM), a proprietary next-generation sequencing assay that measures changes to the adaptive...

2008-09-23 06:00:32

DioGenix Inc. today announced its sale to Nerveda, Inc., a privately held specialty pharmaceutical and diagnostic company. As consideration for acquiring all of the outstanding stock of DioGenix, Ore Pharmaceuticals, Inc. (NASDAQ: ORXE), the former parent company of DioGenix, received an undisclosed amount of cash, as well as a small royalty on sales of a multiple sclerosis (MS) diagnostic. Pursuant to the stock purchase agreement, Nerveda will fund DioGenix with at least $5 million to...